Evaxion AS (EVAX)
3.12
+0.04
(+1.30%)
USD |
NASDAQ |
Sep 04, 16:00
3.11
-0.01
(-0.32%)
After-Hours: 20:00
Evaxion Research and Development Expense (Quarterly) : 2.331M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.331M |
| March 31, 2026 | 2.306M |
| December 31, 2025 | 2.558M |
| September 30, 2025 | 3.078M |
| June 30, 2025 | 2.194M |
| March 31, 2025 | 2.158M |
| December 31, 2024 | 2.239M |
| September 30, 2024 | 2.622M |
| June 30, 2024 | 2.75M |
| March 31, 2024 | 2.829M |
| December 31, 2023 | 2.317M |
| September 30, 2023 | 2.815M |
| June 30, 2023 | 2.933M |
| March 31, 2023 | 3.869M |
| Date | Value |
|---|---|
| December 31, 2022 | 4.106M |
| September 30, 2022 | 4.047M |
| June 30, 2022 | 4.085M |
| March 31, 2022 | 4.792M |
| December 31, 2021 | 6.138M |
| September 30, 2021 | 4.403M |
| June 30, 2021 | 5.104M |
| March 31, 2021 | 3.883M |
| December 31, 2020 | 2.860M |
| September 30, 2020 | 3.006M |
| June 30, 2020 | 2.592M |
| March 31, 2020 | 2.510M |
| December 31, 2019 | 2.963M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Autolus Therapeutics Plc | 27.95M |
| Cellectis SA | 20.89M |
| DBV Technologies SA | 28.96M |
| Ascendis Pharma A/S | 85.39M |
| Akari Therapeutics Plc | 2.081M |